Surrozen (NASDAQ:SRZN) Upgraded at Guggenheim

Guggenheim upgraded shares of Surrozen (NASDAQ:SRZN) from a neutral rating to a buy rating in a research report released on Friday morning, Marketbeat.com reports. The firm currently has $45.00 target price on the stock.

Surrozen Trading Up 19.4 %

NASDAQ:SRZN opened at $17.02 on Friday. Surrozen has a 1-year low of $6.00 and a 1-year high of $18.17. The company’s fifty day moving average price is $10.92 and its 200-day moving average price is $9.90.

Surrozen (NASDAQ:SRZN) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.77) by $2.33. The business had revenue of $10.00 million during the quarter. On average, equities research analysts anticipate that Surrozen will post -7.16 EPS for the current fiscal year.

Institutional Trading of Surrozen

A number of hedge funds and other institutional investors have recently made changes to their positions in SRZN. CVI Holdings LLC acquired a new stake in Surrozen during the second quarter valued at $711,000. Stonepine Capital Management LLC acquired a new stake in Surrozen during the second quarter valued at $724,000. Nantahala Capital Management LLC acquired a new stake in Surrozen during the second quarter valued at $2,050,000. Finally, Armistice Capital LLC acquired a new stake in Surrozen during the second quarter valued at $2,080,000. Institutional investors and hedge funds own 66.57% of the company’s stock.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.